Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice

Cheng Xue Qin, Lauren T. May, Renming Li, Nga Cao, Sarah Rosli, Minh Deo, Amy E Alexander, Duncan Horlock, Jane E. Bourke, Yuan H. Yang, Alastair G. Stewart, David M. Kaye, Xiao Jun Du, Patrick M. Sexton, Arthur Christopoulos, Xiao Ming Gao, Rebecca H. Ritchie

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

Effective treatment for managing myocardial infarction (MI) remains an urgent, unmet clinical need. Formyl peptide receptors (FPR) regulate inflammation, a major contributing mechanism to cardiac injury following MI. Here we demonstrate that FPR1/FPR2-biased agonism may represent a novel therapeutic strategy for the treatment of MI. The small-molecule FPR1/FPR2 agonist, Compound 17b (Cmpd17b), exhibits a distinct signalling fingerprint to the conventional FPR1/FPR2 agonist, Compound-43 (Cmpd43). In Chinese hamster ovary (CHO) cells stably transfected with human FPR1 or FPR2, Compd17b is biased away from potentially detrimental FPR1/2-mediated calcium mobilization, but retains the pro-survival signalling, ERK1/2 and Akt phosphorylation, relative to Compd43. The pathological importance of the biased agonism of Cmpd17b is demonstrable as superior cardioprotection in both in vitro (cardiomyocytes and cardiofibroblasts) and MI injury in mice in vivo. These findings reveal new insights for development of small molecule FPR agonists with an improved cardioprotective profile for treating MI.

Original languageEnglish
Article number14232
Number of pages13
JournalNature Communications
Volume8
DOIs
Publication statusPublished - 7 Feb 2017

Keywords

  • heart failure
  • receptor pharmacology

Cite this